Pages that link to "Q33582654"
Jump to navigation
Jump to search
The following pages link to Risperidone. A pharmacoeconomic review of its use in schizophrenia (Q33582654):
Displaying 27 items.
- Olanzapine: an updated review of its use in the management of schizophrenia (Q32058541) (← links)
- Olanzapine. A pharmacoeconomic review of its use in schizophrenia (Q33761583) (← links)
- Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin? (Q33972245) (← links)
- Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study (Q34374891) (← links)
- Use of atypical antipsychotics in a Veterans Affairs hospital (Q35009404) (← links)
- Economic evaluations of novel antipsychotic medications: a literature review (Q35068139) (← links)
- Risperidone in acute and long-term therapy of schizophrenia--a clinical profile (Q35612445) (← links)
- Long-acting risperidone: a review of its use in schizophrenia (Q35631406) (← links)
- Cost comparisons of olanzapine and risperidone in treating schizophrenia (Q35638077) (← links)
- Impact of atypical antipsychotics on quality of life in patients with schizophrenia (Q35936881) (← links)
- Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study (Q38636867) (← links)
- Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models (Q36370291) (← links)
- Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives (Q36895534) (← links)
- Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic (Q37418931) (← links)
- Impact of antipsychotic medication on the cost of schizophrenia (Q37609382) (← links)
- Comparison of older and newer neuroleptics for the treatment of schizophrenia (Q37610288) (← links)
- Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada) (Q37672702) (← links)
- The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review (Q38167693) (← links)
- Design of a Drug-in-Adhesive Transdermal Patch for Risperidone: Effect of Drug-Additive Interactions on the Crystallization Inhibition and In Vitro/In Vivo Correlation Study (Q39492095) (← links)
- Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy (Q40571172) (← links)
- The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia (Q42659773) (← links)
- Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels (Q43540993) (← links)
- Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis (Q46896761) (← links)
- Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany (Q46896765) (← links)
- The promises and pitfalls of pharmacoeconomics in schizophrenia (Q51945314) (← links)
- Quality of life in patients with schizophrenia in five European countries: the EPSILON study (Q51958098) (← links)
- [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics] (Q78659012) (← links)